Update on progress in HIV vaccine development.
The 19th Conference on Retroviruses and Opportunistic Infections heralded the arrival of a new crop of potent, broadly neutralizing antibodies against HIV. This advance has given the entire vaccine field enormous hope that it will be possible one day to develop an antibody-based vaccine for HIV. However, substantial obstacles still exist in the induction of these antibodies by vaccination, given the enormous number of somatic mutations needed to develop these highly efficient antibodies. It is likely that follicular helper T cells will be involved in the development of these antibodies, and this will be a key area of interest in the future. Cellular immune responses will also be an important part of any vaccine regimen. Evidence showed that protection provided by an attenuated vaccine correlated with the frequency of vaccine-induced helper cells and killer cells, underlining the importance of these key immune cells. An alternative approach to the development of potent neutralizing antibodies was presented as part of an update on the Thai Phase III Vaccine Trial RV144. Data were shown suggesting that binding antibodies may play a role in protection from HIV infection.
University of Miami Miller School of Medicine, FL, USA.
David I
DI
Watkins
D016915:AIDS Vaccines / Q000276:immunology*; D000163:Acquired Immunodeficiency Syndrome / Q000517:prevention & control* / Q000628:therapy*; D057134:Antibodies, Neutralizing / Q000276:immunology; D035843:Biomedical Research / Q000639:trends; D055808:Drug Discovery / Q000639:trends; D015483:HIV Antibodies / Q000276:immunology; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000276:immunology
D016915:AIDS Vaccines; D057134:Antibodies, Neutralizing; D015483:HIV Antibodies